S. Bahmanyar

First name

S.

Last name

Bahmanyar

Korhonen, P., Heintjes, E. M., Williams, R., Hoti, F., Christopher, S., Majak, M., et al. (2016). Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries. Bmj. http://doi.org/10.1136/bmj.i3903

View

Strongman, H., Korhonen, P., Williams, R., Bahmanyar, S., Hoti, F., Christopher, S., et al. (2017). Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2016-000364

View

Margulis, A. V., Linder, M., Arana, A., Pottegard, A., Berglind, I. A., Bui, C. L., et al. (2018). Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS One. http://doi.org/10.1371/journal.pone.0204456

View

Strongman, H., Christopher, S., Majak, M., Williams, R., Bahmanyar, S., Linder, M., et al. (2018). Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2017-000481

View

Phiri, K., Hallas, J., Linder, M., Margulis, A., Suehs, B., Arana, A., et al. (2021). A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Curr Med Res Opin. http://doi.org/10.1080/03007995.2021.1891035

View